Pedro Perez on Deep Vein Thrombosis in 2026: Getting the First Decisions Right
Pedro Perez, Vascular Consultant – PERT and VTE Program Builder at Argon Medical Devices, Inc., shared on LinkedIn:
”Deep Vein Thrombosis in 2026: Getting the First Decisions Right
Even with major advances in treatment, outcomes in deep vein thrombosis (DVT) still depend heavily on early decisions.
Many preventable complications—such as pulmonary embolism, bleeding, recurrence, and long-term leg symptoms—don’t happen because we lack treatment options.
They happen when the early steps aren’t clear or consistent.
A few principles that still matter:
• Assess risk before jumping to testing
• Use blood tests thoughtfully, not automatically
• Imaging should be targeted, not excessive
• Treatment plans should be intentional and reassessed
• The first few months after diagnosis are critical
When DVT is approached in a structured, step-by-step way, outcomes improve and unnecessary interventions can often be avoided.
Clear decision-making early on remains one of the most powerful tools in managing DVT—now and in the years ahead.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia
-
Mar 12, 2026, 11:33Kymentie Ferdinande: New Insights Into Platelet Function and Thrombus Formation in Cirrhosis
-
Mar 12, 2026, 11:17Tareq Abadl: Why Do Some People Bruise And Bleed So Easily?
-
Mar 12, 2026, 11:15Matthew Flick: The Interplay of the Fibrinogen αC-Region, Hypofibrinogenemia, and GPVI in Arterial Thrombosis
-
Mar 12, 2026, 11:08Stephen Twumasi: The Impact of Hepatitis B Infection on the Coagulation System During Pregnancy
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease
-
Mar 12, 2026, 10:36Cynthia Dunbar: Retiring From NIH After 39 Years to Advance Advocacy and Research in Hematology
-
Mar 11, 2026, 23:05Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority